7:00 AM - 8:15 AM

Registration and Networking Breakfast

sponsored by

8:15 AM - 8:20 AM

Welcome remarks

sponsored by

8:20 AM - 8:40 AM

In conversation with Aviv Regev

An in-depth discussion featuring the Founder and Editor of Endpoints News, John Carroll, and the Executive VP, Head of Genentech Research & Early Development (gRED) at Genentech, Aviv Regev.

 

Aviv Regev

Aviv Regev

Executive VP, Head of Genentech Research & Early Development (gRED)
Genentech

John Carroll

John Carroll

Founder & Editor
Moderator
Endpoints News

sponsored by

8:40 AM - 8:55 AM

From Wall Street to C-Suite: In conversation with Jami Rubin

An in-depth conversation featuring Endpoints Executive Editor Drew Armstrong and Jami Rubin, the Chief Financial Officer at Boundless Bio (and a famed former investment analyst at Goldman Sachs), covering the recent Boundless IPO and Jami’s long career in the biopharma industry.

Jami Rubin

Jami Rubin

Chief Financial Officer
Boundless Bio

Drew Armstrong

Drew Armstrong

Executive Editor
Moderator
Endpoints News

sponsored by

PWC
8:55 AM - 9:15 AM

Gene therapy’s ‘generation 0’: A fireside chat with Tom Klima

Endpoints senior biopharma correspondent Andy Dunn talks with Tom Klima, Chief Commercial & Operating Officer at bluebird bio, about lessons learned from being one of the earliest gene therapy companies.

Tom Klima

Tom Klima

Chief Commercial & Operating Officer
bluebird bio

Andrew Dunn

Andrew Dunn

Biopharma Correspondent
Moderator
Endpoints News

sponsored by

9:15 AM - 9:45 AM

Building gene therapy platforms that work — and scale — sustainably

The first round of gene therapies have left the lab and secured FDA approval, but some of the companies that were first out the gate are struggling. What have we learned about creating viable and scalable gene therapies, and what are the lessons to take away from ‘generation 0’?

Benjamin Oakes

Benjamin Oakes

Co-Founder, President, and CEO
Scribe Therapeutics

Tom Klima

Tom Klima

Chief Commercial & Operating Officer
bluebird bio

Andrew Dunn

Andrew Dunn

Biopharma Correspondent
Moderator
Endpoints News

sponsored by

9:45 AM - 10:00 AM

Networking Break

sponsored by

10:00 AM - 10:25 AM

The winners and losers of biotech’s comeback

IPOs are back and biopharmas are raising money. Q1 was marked by signs of life from the market, and the outlook is optimistic. Who came out on top in the bounceback — and who was left behind?

Lynn Seely

Lynn Seely

President & CEO
Lyell Immunopharma

Matt Gline

Matt Gline

CEO
Roivant Sciences

Andrew Lam

Andrew Lam

Managing Director, Head of Biotech Private Equity
Ally Bridge Group

Kurt von Emster

Kurt von Emster

Managing Partner, Head of Life Sciences
Abingworth

John Carroll

John Carroll

Founder & Editor
Moderator
Endpoints News

sponsored by

Catalent
10:25 AM - 10:55 AM

Unlocking Value: why mid-size pharma might be your perfect match

In the dynamic landscape of the pharmaceutical industry, partnerships play a pivotal role in driving innovation, accessing new markets, and enhancing competitive advantage. While big pharma acquisitions often dominate the headlines, mid-size pharmaceutical companies such as Ipsen offer a unique value proposition in collaborations. In this panel we will discuss where mid-size pharma are playing their strengths to secure deals that could dominate future innovations and how their size could offer an advantage to potential partners.

Bill Newell

Bill Newell

CEO
Sutro Biopharma

Geeta Vemuri

Geeta Vemuri

Founder & Managing Partner
Agent Capital

Philippe Lopes-Fernandes

Philippe Lopes-Fernandes

Executive VP, Chief Business Officer
Ipsen

John Carroll

John Carroll

Founder & Editor
Moderator
Endpoints News

sponsored by

Ipsen
10:55 AM - 11:15 AM

In conversation with Matt Gline

An in-depth conversation featuring Endpoints Executive Editor Drew Armstrong and CEO of Roivant Sciences, Matt Gline.

Matt Gline

Matt Gline

CEO
Roivant Sciences

Drew Armstrong

Drew Armstrong

Executive Editor
Moderator
Endpoints News

sponsored by

11:15 AM - 11:45 AM

US-China tensions and the future of global biopharma partnerships

Chinese manufacturing is squarely in the crosshairs of US regulators, and regardless of whether legislation advances, the relationship between US and Chinese companies has already been changed, likely for good. Our panel explores the latest policy development and how drug developers are grappling with the fast-changing landscape.

Helen Chen

Helen Chen

Global Sector Co-Head, Healthcare and Life Sciences | Greater China Managing Partner
L.E.K. Consulting

Tim Opler

Tim Opler

Managing Director
Stifel

Nick Shipley

Nick Shipley

Former Chief Advocacy Officer, BIO
Biopharma Consultant, Former BIO and PhRMA Senior Executive

Amber Tong

Amber Tong

Senior Editor
Moderator
Endpoints News

sponsored by

OWKIN